Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 257

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 257
---
 securities markets, including current market valuations of publicly traded companies considered comparable to our company. We cannot assure you, however, that the price at which the ordinary shares, units or rights will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our ordinary shares, units or rights will develop and continue after this offering. Listing We have applied to list our units on Nasdaq under the symbol “DMAAU”. We cannot guarantee that our securities will be approved for listing on Nasdaq. We expect that our units will be listed on Nasdaq on or promptly after the date of this prospectus. We expect that our ordinary shares and rights will be listed under the symbols “DMAA” and “DMAAR,” respectively, once the ordinary shares and rights begin separate trading. Expression of Interest The non -managingsponsor investors have expressed to us an interest in purchasing up to an aggregate of approximately $39.8million of the units in this offering at the offering price (considering the exercise in full of the underwriters’ over -allotmentoption), or up to 19.9% of this offering. None of the non -managingsponsor investors has expressed to us an interest in purchasing more than 9.9% of the units to be sold in this offering, except one non -managingsponsor investor has expressed to us an interest in purchasing 19.9% of the units to be sold in this offering. There can be no assurance that the non -managingsponsor investors will acquire any units, either directly or indirectly, in this offering, or as to the amount of the units the non -managingsponsor investors will retain, if any, prior to or upon the consummation of our initial business combination. Because these expressions of interest are not binding agreements or commitments to purchase, more units in this offering, non -managingsponsor investors may determine to purchase fewer units in this offering, or none at all. In addition, the underwriters have full discretion to allocate the units to investors and may determine to sell fewer units to the non -managingsponsor investors, or none at all, and the purchase of the non -managingsponsor membership interests is not contingent upon the participation in this offering or vice -versa. Depending on how many units are purchased by the non -managingsponsor investors, the post -offeringtrading volume, volatility and liquidity of our securities may be reduced